BRD3

Across TCGA pan-cancer cohorts, BRD3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BRD3’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where BRD3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BRD3 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

PDAC, COAD, and LUAD are the cancer types where BRD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BRD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	−0.219	.006	6	view →
COAD	All	All	+0.141	.002	6	view →
LUAD	Female	All	−0.126	<.001	5	view →
LSCC	Male	III,IV	−0.139	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BRD3–PDAC

Open the PDAC breakdown →